Global /Japan /Healthcare /Drug Manufacturers - General /4578
chevron_leftBack

Otsuka Holdings Co., Ltd.

4578
TSE: 4578 Delayed
6,707JPY 0.1%
46.87 USD
As of 24 April 2025, Otsuka Holdings Co., Ltd. has a market cap of $24.57B USD, ranking #796 globally and #55 in Japan. It ranks #69 in the Healthcare sector, and #19 in the Drug Manufacturers - General industry.
Global Rank
796
Country Rank
55
Sector Rank
69
Industry Rank
19
Key Stats
Market Cap
$24.57BUSD
3.5T JPY
Enterprise Value
$23.12BUSD
3.31T JPY
Revenue (TTM)
$16.35BUSD
2.33T JPY
EBITDA (TTM)
$3.66BUSD
523.97B JPY
Net Income (TTM)
$2.41BUSD
343.12B JPY
EBITDA Margin
22%
Profit Margin
15%
PE Ratio
10.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Makoto Inoue open_in_new
Employees
35,338
Founded
1921
Website
otsuka.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.1% -1.4% -18% -16% -26% 5.8%
Upcoming Earnings
Earnings Date
Wed, Apr 30

Markets

Exchange Ticker Price
Tokyo Stock Exchange
MIC: XTKS
PRIMARY
4578
大塚ホールディングス株式会社
ISIN: JP3188220002
Shares Out.:
537.093M1 Shares Float: 410.171M2
TV:
SA:
YF:
GF:
BA:
MS:
6.71K JPY
Frankfurt Stock Exchange
MIC: XFRA
OS1
大塚ホールディングス株式会社
ISIN: JP3188220002
Shares Out.:
537.093M1 Shares Float: 410.177M2
TV:
SA:
YF:
GF:
BA:
OS1
MS:
41.00 EUR
OTC Markets
MIC: OTCM
OTSKF
大塚ホールディングス株式会社
ISIN: JP3188220002
TV:
SA:
YF:
GF:
BA:
MS:
47.80 USD
OTC Markets
MIC: OTCM
OTSKY
大塚ホールディングス株式会社 ADR
ISIN: US6891641010
TV:
SA:
YF:
GF:
BA:
MS:
23.56 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)
Name
Market Cap diff.
Chugai Pharmaceutical Co., Ltd.
4519
$94.63B
13.48T JPY
285%
Daiichi Sankyo Company, Ltd.
4568
$43.36B
6.18T JPY
77%
Astellas Pharma Inc.
4503
$17.19B
2.45T JPY
-30%
Kyowa Kirin Co., Ltd.
4151
$8.13B
1.16T JPY
-67%
Ono Pharmaceutical Co., Ltd.
4528
$5.59B
796.62B JPY
-77%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.81B
3K%
Johnson & Johnson
JNJ
$374.44B
1K%
AbbVie Inc.
ABBV
$313.2B
1K%
Novo Nordisk A/S
NOVO-B
$276.68B
1.82T DKK
1K%
Roche Holding AG
RO
$246.36B
204.44B CHF
903%